2023-10-24 10:45:00

European Commission Expands Merck's VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) Indication to

Logo Benzinga
Benzinga
By Business Wire

Merck MRK, known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved an expanded indication for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years of age. The approval facilitates availability of VAXNEUVANCE for this population in all 27 European Union (EU) Member States plus Iceland, Norway and Lichtenstein. VAXNEUVANCE is also indicated in the EU for active immunization for the prevention of invasive disease and pneumonia caused by S. pneumoniae in individuals 18 years of age and older. The use of VAXNEUVANCE in the EU should be in accordance with official recommendations.

AD
AD

VAXNEUVANCE was developed to maintain a strong immune response to serotypes included in currently available pneumococcal conjugate vaccines, or PCVs, while expanding coverage to disease-causing serotypes that can pose substantial risk to infants and children, said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. With this approval, we are pleased to bring an important new PCV option to a vulnerable population in Europe, including infants less than one year of age, who typically experience the highest rates of disease.

Continue read on benzinga.com

AD
Logo Nasdaq
Business / FinanceBy Rtt News2023-10-14 11:40:21
(RTTNews) - Takeda (TAK) announced the CHMP of the European Medicines Agency recommended the approval of the company's dengue vaccine candidate, TAK-003, for...

Logo GlobeNewswire
EconomyPress Release2023-10-20 13:01:00
Vaccine Contract Manufacturing Market, By Type (Inactivated Vaccines, Messenger RNA Vaccines, Viral Vector Vaccines, Conjugate Vaccines, Live-attenuated...

Logo U.S. News & World Report
PoliticsBy Associated Press2023-10-14 12:05:02
LONDON (AP) The European Medicines Agency on Friday recommended the authorization of a dengue vaccine made by the Japanese pharmaceutical Takeda that could...

Logo The Motley Fool
MarketsBy David Jagielski2023-10-18 13:25:00
A big challenge with Moderna ( MRNA 3.92%) right now is that many investors see it as a COVID-19 stock and not much else. The company is developing more...

Logo Nasdaq
Business / FinanceBy Rtt News2023-10-10 09:36:51
(RTTNews) - The FDA has approved GSK plc's (GSK) Boostrix vaccine for immunization during the third trimester of pregnancy to prevent pertussis, commonly...

Logo Nasdaq
MarketsBy Zacks2023-10-10 15:21:00
GSK plc GSK announced that the FDA expanded Boostrixs label for immunization during pregnancy to help prevent pertussis (whooping cough) in infants not older...

Logo CNBC
Business / FinanceBy Spencer Kimball2023-10-19 21:30:38
Key Points The Vaccines for Children program provides vaccines to kids under age 19 whose families cannot afford them. Children are eligible for the program...

Logo Nasdaq
MarketsBy Zacks2023-10-13 14:15:00
This week, the FDA granted emergency use authorization (EUA) to Omicron BA.4/BA.5 adapted COVID-19 booster vaccinesof Pfizer PFE / BioNTech BNTX and Moderna...

Logo Nasdaq
TechnologyBy Zacks2023-10-14 11:07:00
For Immediate Release Chicago, IL October 14, 2023 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research...

Logo MarketWatch
MarketsBy Anthony O Goriainoff2023-10-10 06:18:00
GSK PLC GSK, -0.66% said Monday that the U.S. Food and Drug Administration has approved Boostrix for immunization during the third trimester of pregnancy to...

Logo Benzinga
Business / FinanceBy Business Wire2024-09-27 10:45:00
KEYTRUDA now approved for 23 uses in 13 different types of cancer in Japan Merck MRK, known as MSD outside of the United States and Canada, today announced...

Logo Nasdaq
MarketsBy Zacks2024-09-26 16:39:00
Shares of Valneva VALN have dropped 66.2% in the past six months compared with the industry s 42.6% decline. Image Source: Zacks Investment Research The...

Logo Benzinga
Business / FinanceBy Business Wire2023-09-29 10:45:00
Merck MRK, known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional...

Logo EIN Presswire
PoliticsPress Release2023-10-21 15:35:54
WASHINGTON, DC, USA, October 21, 2023 / EINPresswire.com / -- A statement from Bob Blancato, Executive Director of the National Association of Nutrition and...

Logo Nasdaq
MarketsBy Rtt News2023-10-12 11:29:54
(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Wednesday that Health Canada has granted approval for KEYTRUDA...

Logo Nasdaq
MarketsBy Zacks2023-10-13 15:27:00
Shares of Moderna MRNA were up 8.3% on Oct 12 after management announced that partner Merck MRK exercised an option under an existing collaboration...

Logo RTTNews
EconomyBy Rtt News Staff Writer2023-10-12 11:29:54
Merck & Co., Inc. ( MRK ), known as MSD outside the U.S. and Canada, announced Wednesday that Health Canada has granted approval for KEYTRUDA...

Logo U.S. News & World Report
PoliticsBy Health Day2023-10-21 11:02:00
By Cara Murez and Robin Foster HealthDay Reporters FRIDAY, Oct. 21, 2022 (HealthDay News) In an unanimous vote on Thursday, a panel of U.S. vaccine experts...

Logo CNN
MarketsBy Liz Szabo2023-10-18 10:23:13
Maybe youve never heard of the Epstein-Barr virus. But it knows all about you. Chances are, its living inside you right now. About 95% of American adults are...

Logo CNBC
Business / FinanceBy Spencer Kimball2023-10-12 14:07:34
Key Points Moderna's messenger RNA vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest...